US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

117.99

-2.8100-2.33%

Volume:18.25K

Turnover:2.14M

Market Cap:1.59B

PE:-33.43

High:119.08

Open:119.08

Low:116.30

Close:120.80

52wk High:151.18

52wk Low:18.23

Shares:13.44M

Float Shares:8.40M

Volume Ratio:0.51

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.5291

EPS(LYR):-7.8322

ROE:-301.19%

ROA:-47.54%

PB:40.98

PE(LYR):-15.06

Loading ...

Overview Company News Filings

Palvella Therapeutics price target raised to $209 from $143 at JonesResearch

Palvella Therapeutics Is Maintained at Buy by HC Wainwright & Co.

BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet

Palvella Therapeutics Up Over 34%, on Track for Highest Close Since March 2023 -- Data Talk

Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright

Palvella Therapeutics Inc. : H.c. Wainwright Raises Target Price to $255 From $200

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy

Mizuho Adjusts Price Target on Palvella Therapeutics to $250 From $205, Maintains Outperform Rating

MT Newswires Live

Palvella Therapeutics Shares Jump 23% Premarket After Co's Skin Disease Drug Meets Late-Stage Trial Goal

THOMSON REUTERS

BUZZ-Palvella jumps after rare disease treatment shows improvement in late-stage study

Palvella Therapeutics Shares Jump on Positive Trial Data for Microcystic Lymphatic Malformations Drug

Palvella Therapeutics’ qtorin meets primary endpoint in lymphatic malformations

BRIEF-Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study Of Qtorin™

Palvella Therapeutics Inc: Palvella Plans to Submit a New Drug Application to FDA in Second Half of 2026

THOMSON REUTERS

Palvella Therapeutics Inc - Qtorin™ Rapamycin Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS

Palvella Therapeutics Inc - Phase 3 Trial Meets Primary Endpoint With Significant Improvement

THOMSON REUTERS

Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) in Microcystic Lymphatic Malformations

THOMSON REUTERS

Palvella - Achieved Statistical Significance on Pre-Specified Key Secondary Endpoint (P<0.001) & All 4 Secondary Efficacy Endpoints (All P<0.001)

THOMSON REUTERS

Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations

Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVLA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":117.99,"timestamp":1773843106134,"preClose":120.8,"halted":0,"volume":18246,"delay":0,"changeRate":-0.02326158940397353,"floatShares":8398100,"shares":13436500,"eps":-3.529122,"marketStatus":"Trading","change":-2.81,"latestTime":"03-18 10:12:07 EDT","open":119.08,"high":119.08,"low":116.2984,"amount":2144181.24444,"amplitude":0.023026,"askPrice":117.99,"askSize":103,"bidPrice":116,"bidSize":42,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":120.8,"preHourTrading":{"tag":"盘前","latestPrice":117.68,"preClose":120.8,"latestTime":"08:05 EDT","volume":10,"amount":1176.8000000000002,"timestamp":1773835511621,"change":-3.12,"changeRate":-0.025828,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":120.8,"preClose":120.8,"latestTime":"17:40 EDT","volume":5215,"amount":629978.63,"timestamp":1773783650538,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.513208,"impliedVol":0.7605,"impliedVolPercentile":0.6773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-47.54%","roe":"-301.19%","lyrEps":-7.832217,"volumeRatio":0.513208,"shares":13436500,"dividePrice":0,"high":119.08,"amplitude":0.023026,"preClose":120.8,"low":116.2984,"week52Low":18.225,"pbRate":"40.98","week52High":151.18,"institutionHeld":0,"latestPrice":117.99,"committee":-0.42069,"eps":-3.529122,"divideRate":0,"volume":18246,"delay":0,"ttmEps":-3.529122,"open":119.08,"prevYearClose":104.67,"prevWeekClose":122.06,"prevMonthClose":135.02,"prevQuarterClose":104.67,"fiveDayClose":139.69,"twentyDayClose":79.6,"sixtyDayClose":96.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2025-05-15","symbol":"PVLA","fiscalQuarterEnding":"2025/03","expectedEps":-3.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1767844800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-03-17","current":-33.433245,"percent":0.03537,"low":-60.48704,"twenty":-30.64006,"median":-18.188229,"eighty":19.083855,"high":46.119317,"avg":-12.723858,"sd":24.785399,"marketCap":1693669564},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-17","current":-51.398081,"twenty":-30.64006,"median":-18.188229,"eighty":19.083855,"marketCap":1693669564}],"updateTime":1773843127077},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614429744","title":"Palvella Therapeutics price target raised to $209 from $143 at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2614429744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614429744?lang=en_us&edition=fundamental","pubTime":"2026-02-25 02:55","pubTimestamp":1771959317,"startTime":"0","endTime":"0","summary":"JonesResearch analyst Catherine Novack raised the firm’s price target on Palvella Therapeutics (PVLA) to $209 from $143 and keeps a Buy rating on t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-209-from-143-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-209-from-143-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2614374481","title":"Palvella Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614374481","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614374481?lang=en_us&edition=fundamental","pubTime":"2026-02-25 02:21","pubTimestamp":1771957260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2026 13:21 ET (18:21 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2613745858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet","url":"https://stock-news.laohu8.com/highlight/detail?id=2613745858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613745858?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:55","pubTimestamp":1771948559,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSetEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZK170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRG","ELAN","KDP","ROAD","WHR","VIR","BOOM","KEYS","FRPT","THR","ITRI","PVLA","CNP","DPZ","FDS","HMYY","ELIS","TARA","AMDD","AMYY","HSIC","HIMZ","FGL","AES","CVS","LRMR","OKE","SEG","ED","OWL","ANPA","ALUR","KTOS","CLVT","AWI","NEMG","HD","SHLS","TNC","AU","EXPD","PPL"],"gpt_icon":1},{"id":"2613431377","title":"Palvella Therapeutics Up Over 34%, on Track for Highest Close Since March 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2613431377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613431377?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:33","pubTimestamp":1771947180,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc.  is currently at $117.90, up $30.06 or 34.22%. --Would be highest close since March 28, 2023, when it closed at $118.40. --On pace for largest percent increase since July 24, 2024, when it rose 88.6%. --Currently up four consecutive days; up 48.12% over this period. --Longest winning streak since Dec. 8, 2025, when it rose for four straight trading days. --Up 53.74% month-to-date; on pace for best month since July 2025, when it rose 62.29%. --Down 84.4% from its all-time closing high of $756.00 on Feb. 13, 2018. --Up 510.56% from 52 weeks ago , when it closed at $19.31. --Up 527.13% from its 52-week closing low of $18.80 on Feb. 26, 2025. --Traded as high as $127.69; highest intraday level since Feb. 21, 2023, when it hit $129.79","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613087748","title":"Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2613087748","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613087748?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:10","pubTimestamp":1771945840,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELV...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-255-from-200-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-255-from-200-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2613748438","title":"Palvella Therapeutics Inc. : H.c. Wainwright Raises Target Price to $255 From $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613748438?lang=en_us&edition=fundamental","pubTime":"2026-02-24 23:09","pubTimestamp":1771945758,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nAZN4SI14W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613179777","title":"BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2613179777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613179777?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:12","pubTimestamp":1771942333,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Advanced Micro Devices, Constellation Energy, NRG EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL6N3ZK0O3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KDP","LLYX","DAMD","OWL","VIR","CEG","LRMR","BEZ","AMDG","NWMX","ELIL","RJF","AES","AMYY","AWI","FRPT","HD","HMYY","ROAD","AU","AMDU","AMUU","PVLA","BEG","PPL","KTOS","BEX","HIYY","AMDW","GPC","NEMG","AMDD","HIMY","CEGX","KEYS","AMDY","NRG","ELIS","LLYZ","AMD","HIMZ","KTUP","WHR","THR"],"gpt_icon":1},{"id":"2613371413","title":"Mizuho Adjusts Price Target on Palvella Therapeutics to $250 From $205, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2613371413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613371413?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:24","pubTimestamp":1771939490,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $191.94, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","MFG"],"gpt_icon":0},{"id":"2613719047","title":"Palvella Therapeutics Shares Jump 23% Premarket After Co's Skin Disease Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719047?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:53","pubTimestamp":1771937582,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nFWN3ZK0IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613271978","title":"BUZZ-Palvella jumps after rare disease treatment shows improvement in late-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2613271978","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613271978?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:49","pubTimestamp":1771937366,"startTime":"0","endTime":"0","summary":"BUZZ-Palvella jumps after rare disease treatment shows improvement in late-stage study** Shares of drug developer Palvella Therapeutics PVLA.O jump 28.1% to $112 premarket** Co says its experimental topical treatment for patients with a type of rare skin and soft tissue disease met main goal in a late-stage study** Co was testing its experimental therapy, Qtorin rapamycin, to treat microcystic lymphatic malformations ** MLMs are rare congenital conditions characterized by clusters of small, fluid-filled cysts in the lymphatic system, often leading to swelling and discomfort** The therapy showed statistically significant improvement in symptoms on the 7-point scale after 24 weeks, with an average gain of +2.13 points** \"We see today's result as a best-case scenario win, and would be buying into anticipated strength this morning. We believe Palvella shares remain substantially undervalued for the total market opportunity across Qtorin indications\" - Oppenheimer** Palvella plans to submit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL4N3ZK14R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613716687","title":"Palvella Therapeutics Shares Jump on Positive Trial Data for Microcystic Lymphatic Malformations Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2613716687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613716687?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:15","pubTimestamp":1771935300,"startTime":"0","endTime":"0","summary":"Shares of Palvella Therapeutics rose in premarket trading Tuesday after the company reported positive results from its phase 3 trial of its treatment targeting microcystic lymphatic malformations.Shares recently traded 42% higher ahead of the morning bell at $124.89.The clinical-stage biopharmaceutical on Tuesday reported positive topline results from the its Phase 3 Selva study of Qtorin 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations.Microcystic lymphatic malformations, or microcystic LMs, are a rare type of lymphatic malformation made up of very small, abnormal lymphatic cysts which are benign but can cause the occurrence of symptoms.Palvella said the trial also met its primary endpoint with statistically significant improvement as well as a key secondary endpoint and all four additional secondary endpoints.The company plans to submit a new drug application to the Food and Drug Administration for Qtorin in the second half of the year, which could potentiall","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613159947","title":"Palvella Therapeutics’ qtorin meets primary endpoint in lymphatic malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2613159947","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613159947?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:53","pubTimestamp":1771933987,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) announced positive topline results from the company’s Phase 3 SELVA study of qtorin 3.9% rapamycin anhydrous gel for t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-qtorin-meets-primary-endpoint-in-lymphatic-malformations-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-qtorin-meets-primary-endpoint-in-lymphatic-malformations-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613713352","title":"BRIEF-Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study Of Qtorin™","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713352","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613713352?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:37","pubTimestamp":1771933039,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study Of QtorinFeb 24 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS ANNOUNCES POSITIVE T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613718766","title":"Palvella Therapeutics Inc: Palvella Plans to Submit a New Drug Application to FDA in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613718766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613718766?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:30","pubTimestamp":1771932600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613718743","title":"Palvella Therapeutics Inc - Qtorin™ Rapamycin Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2613718743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613718743?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:30","pubTimestamp":1771932600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613718712","title":"Palvella Therapeutics Inc - Phase 3 Trial Meets Primary Endpoint With Significant Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2613718712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613718712?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:30","pubTimestamp":1771932600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613371879","title":"Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2613371879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613371879?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:30","pubTimestamp":1771932600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2613071803","title":"Palvella - Achieved Statistical Significance on Pre-Specified Key Secondary Endpoint (P<0.001) & All 4 Secondary Efficacy Endpoints (All P<0.001)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613071803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613071803?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:30","pubTimestamp":1771932600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA8GSX1W:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2613075817","title":"Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2613075817","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613075817?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:00","pubTimestamp":1771884041,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics to Host Call on Phase 3 SELVA Topline Results for QTORIN Rapamycin Gel in Microcystic Lymphatic Malformations. Palvella Therapeutics Inc. announced it will host a conference call and webcast on Feb. 24, 2026, to discuss topline results from the Phase 3 SELVA clinical trial evaluating QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The company said it plans to release the topline results in a press release at about 6:30 a.m. ET on Feb. 24, 2026, ahead of the call, indicating the results will be presented in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL82W11z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014039.USD","BK4139","BK4588","PVLA","IE00BGHQF748.EUR","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","LU0314104364.USD","NDAQ","BK4585"],"gpt_icon":0},{"id":"2613297334","title":"Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297334","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297334?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:06","pubTimestamp":1771621569,"startTime":"0","endTime":"0","summary":"Kathleen Goin, Chief Operating Officer of Palvella Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL6CnB94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":154,"code":"91000000","status":"200"}]}}